In a recent review, Tanaka and co-workers (2022) discussed the concept of neurodevelopmental disorders that may precede such diseases as schizophrenia and Parkinson’s disease, for which early intervention with kynurenine analogues may have neuroprotective effects [5] Notably, downregulation of the peripheral kynurenine pathway, as achieved by bariatric surgery in obese subjects, was found to be accompanied by reduced peripheral inflammation, as monitored by C-reactive protein, whereas neuroinflammation was not monitored in the obese subjects [111]. The gene discussed is CRP; the disease is Parkinson disease.